Combining anti-TNFR2 and anti-PD-L1 antibodies eradicated tumors, prolonged overall survival in pancreatic cancer, and induced strong antitumor immune memory and secondary prevention by reducing the infiltration of Tregs and TAMs and CD8+ T cell activation in the PDAC microenvironment (figure 7L). Here, CD8A is linked to familial pancreatic carcinoma.